Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Gastrointestinal 1

Conditions

Mesothelioma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 1176Cisplatin 893Pemetrexed 849pembrolizumab 627Paclitaxel 610Docetaxel 539Gemcitabine 428Radiotherapy 393Erlotinib Hydrochloride 381Nivolumab 344Bevacizumab 337Etoposide 297durvalumab 265Drug Therapy 260osimertinib 237atezolizumab 225Radiosurgery 196Gefitinib 186Vinorelbine 149Magnetic Resonance Spectroscopy 132Ipilimumab 129130-nm albumin-bound paclitaxel 125Cetuximab 113anlotinib 106Blood Specimen Collection 106tislelizumab 104Topotecan 103Specimen Handling 102Surgical Procedures, Operative 101Cyclophosphamide 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
MAC321 × Thoracic × Clear all
NCT00063219 2009-08-21

Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 2 Completed
48 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00685204 2008-05-28

TL139

Taxolog Inc.

Phase 2 Unknown
90 enrolled
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡